Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

09 mars 2026 07h30 HE | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of...
02 mars 2026 07h30 HE | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics to Participate in Upcoming March Conferences

Trevi Therapeutics' senior management to participate in March investor conference and healthcare summit
17 févr. 2026 07h30 HE | Source: Trevi Therapeutics, Inc.

Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Trevi Therapeutics' senior management will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.
19 mars 2024 08h07 HE | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

ClearPoint Neuro's partner's completed BLA Submission for Upstaza™ would be first disease-modifying treatment for AADC Deficiency in the US.
11 mai 2022 16h05 HE | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Reports First Quarter 2022 Results

SOLANA BEACH, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
01 mars 2022 16h07 HE | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2021 Results

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
15 févr. 2022 16h05 HE | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Reports Fourth Quarter and Full Year 2021 Preliminary Revenue Results and Guidance for Full Year 2022 Revenue

SOLANA BEACH, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
09 nov. 2021 16h05 HE | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Reports Third Quarter 2021 Results

SOLANA BEACH, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
14 juin 2021 09h15 HE | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro Set to Join Russell 3000® Index

SOLANA BEACH, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...
08 juin 2021 07h30 HE | Source: ClearPoint Neuro, Inc.

ClearPoint Neuro, Inc. Congratulates BlueRock Therapeutics on First Patient Dosed with DA01 in Phase 1 Study in Patients with Advanced Parkinson’s Disease

SOLANA BEACH, Calif., June 08, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the...

Page suivante